오말리주맙 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "오말리주맙" in Korean language version.

refsWebsite

Global rank Korean rank

11nih.gov

4^th place

9doi.org

2^nd place

3^rd place

2tga.gov.au

3,984^th place

1,245^th place

2semanticscholar.org

11^th place

310^th place

2hres.ca

low place

1hpfb-dgpsa.ca

low place

1medicines.org.uk

3,823^rd place

2,321^st place

1europa.eu

68^th place

145^th place

1fda.gov

447^th place

433^rd place

1mfds.go.kr

low place

1,240^th place

1archive.org

6^th place

18^th place

1nejm.org

2,374^th place

1,850^th place

1worldcat.org

5^th place

11^th place

archive.org

Davydov L (January 2005). “Omalizumab (Xolair) for treatment of asthma”. 《Am Fam Physician》 71 (2): 341–2. PMID 15686303.

doi.org

dx.doi.org

Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993). “Humanization of an Antibody Directed Against IgE”. 《The Journal of Immunology》 151 (5): 2623–2632. doi:10.4049/jimmunol.151.5.2623. PMID 8360482.
Schulman ES (October 2001). “Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders”. 《Am J Respir Crit Care Med》 164 (8 Pt 2): S6–11. doi:10.1164/ajrccm.164.supplement_1.2103025. PMID 11704611.
Normansell R, Walker S, Milan SJ, Walters EH, Nair P (January 2014). “Omalizumab for asthma in adults and children”. 《The Cochrane Database of Systematic Reviews》 2014 (1): CD003559. doi:10.1002/14651858.CD003559.pub4. PMC 10981784 |pmc= 값 확인 필요 (도움말). PMID 24414989.
Urgert MC, van den Elzen MT, Knulst AC, Fedorowicz Z, van Zuuren EJ (August 2015). “Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment”. 《The British Journal of Dermatology》 173 (2): 404–15. doi:10.1111/bjd.13845. PMID 25891046. S2CID 22874727.
Bernstein JA, Kavati A, Tharp MD, Ortiz B, MacDonald K, Denhaerynck K, Abraham I (April 2018). “Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence”. 《Expert Opinion on Biological Therapy》 18 (4): 425–448. doi:10.1080/14712598.2018.1438406. PMID 29431518.
Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, Maurer M (June 2016). “Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials”. 《The Journal of Allergy and Clinical Immunology》 137 (6): 1742–1750.e4. doi:10.1016/j.jaci.2015.12.1342. PMID 27040372.
Zuberbier T, Wood RA, Bindslev-Jensen C, Fiocchi A, Chinthrajah RS, Worm M, Deschildre A, Fernandez-Rivas M, Santos AF, Jaumont X, Tassinari P (April 2023). “Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis”. 《J Allergy Clin Immunol Pract》 11 (4): 1134–46. doi:10.1016/j.jaip.2022.11.036. PMID 36529441.
Wong, G (February 2024). “Options for Multiple Food Allergies — Food Avoidance or Pharmacologic Treatment?”. 《New England Journal of Medicine》 (영어) 390 (10): 946–948. doi:10.1056/NEJMe2400807. ISSN 0028-4793. PMID 38407311. S2CID 267929262.
Fanta CH (March 2009). “Asthma”. 《The New England Journal of Medicine》 360 (10): 1002–14. doi:10.1056/NEJMra0804579. PMID 19264689.

europa.eu

ema.europa.eu

“Xolair EPAR”. 《European Medicines Agency (EMA)》. 2018년 9월 17일. 2021년 6월 12일에 확인함.

fda.gov

“FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure”. 《U.S. Food and Drug Administration (FDA)》 (보도 자료). 2024년 2월 16일. 2024년 2월 19일에 확인함. 이 문서는 퍼블릭 도메인 출처의 본문을 포함합니다.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

“Regulatory Decision Summary for Xolair”. 《Drug and Health Products Portal》. 2024년 2월 8일. 2024년 4월 2일에 확인함.

hres.ca

hpr-rps.hres.ca

“Regulatory Decision Summary - Xolair - Health Canada”. 《Government of Canada》. 2021년 7월 14일. 2023년 1월 5일에 확인함.

pdf.hres.ca

Novartis Pharmaceuticals Canada Inc (2017년 9월 26일). “Product Monograph: Pr Xolair Omalizumab” (PDF). 2023년 1월 5일에 확인함.

medicines.org.uk

“Xolair 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2020년 8월 18일. 2021년 6월 12일에 확인함.

mfds.go.kr

nedrug.mfds.go.kr

“식품의약품안전처 의약품통합정보시스템 의약품제품정보 상세보기-졸레어주사(오말리주맙)”. 2024년 4월 27일에 확인함.

nejm.org

Wong, G (February 2024). “Options for Multiple Food Allergies — Food Avoidance or Pharmacologic Treatment?”. 《New England Journal of Medicine》 (영어) 390 (10): 946–948. doi:10.1056/NEJMe2400807. ISSN 0028-4793. PMID 38407311. S2CID 267929262.

nih.gov

ncbi.nlm.nih.gov

Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993). “Humanization of an Antibody Directed Against IgE”. 《The Journal of Immunology》 151 (5): 2623–2632. doi:10.4049/jimmunol.151.5.2623. PMID 8360482.
Schulman ES (October 2001). “Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders”. 《Am J Respir Crit Care Med》 164 (8 Pt 2): S6–11. doi:10.1164/ajrccm.164.supplement_1.2103025. PMID 11704611.
Davydov L (January 2005). “Omalizumab (Xolair) for treatment of asthma”. 《Am Fam Physician》 71 (2): 341–2. PMID 15686303.
Normansell R, Walker S, Milan SJ, Walters EH, Nair P (January 2014). “Omalizumab for asthma in adults and children”. 《The Cochrane Database of Systematic Reviews》 2014 (1): CD003559. doi:10.1002/14651858.CD003559.pub4. PMC 10981784 |pmc= 값 확인 필요 (도움말). PMID 24414989.
Urgert MC, van den Elzen MT, Knulst AC, Fedorowicz Z, van Zuuren EJ (August 2015). “Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment”. 《The British Journal of Dermatology》 173 (2): 404–15. doi:10.1111/bjd.13845. PMID 25891046. S2CID 22874727.
Bernstein JA, Kavati A, Tharp MD, Ortiz B, MacDonald K, Denhaerynck K, Abraham I (April 2018). “Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence”. 《Expert Opinion on Biological Therapy》 18 (4): 425–448. doi:10.1080/14712598.2018.1438406. PMID 29431518.
Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, Maurer M (June 2016). “Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials”. 《The Journal of Allergy and Clinical Immunology》 137 (6): 1742–1750.e4. doi:10.1016/j.jaci.2015.12.1342. PMID 27040372.
Zuberbier T, Wood RA, Bindslev-Jensen C, Fiocchi A, Chinthrajah RS, Worm M, Deschildre A, Fernandez-Rivas M, Santos AF, Jaumont X, Tassinari P (April 2023). “Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis”. 《J Allergy Clin Immunol Pract》 11 (4): 1134–46. doi:10.1016/j.jaip.2022.11.036. PMID 36529441.
Wong, G (February 2024). “Options for Multiple Food Allergies — Food Avoidance or Pharmacologic Treatment?”. 《New England Journal of Medicine》 (영어) 390 (10): 946–948. doi:10.1056/NEJMe2400807. ISSN 0028-4793. PMID 38407311. S2CID 267929262.
Fanta CH (March 2009). “Asthma”. 《The New England Journal of Medicine》 360 (10): 1002–14. doi:10.1056/NEJMra0804579. PMID 19264689.

dailymed.nlm.nih.gov

“Xolair- omalizumab injection, solution Xolair PFS- omalizumab injection, solution”. 《DailyMed》. 2020년 5월 11일. 2020년 12월 6일에 확인함.

semanticscholar.org

api.semanticscholar.org

Urgert MC, van den Elzen MT, Knulst AC, Fedorowicz Z, van Zuuren EJ (August 2015). “Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment”. 《The British Journal of Dermatology》 173 (2): 404–15. doi:10.1111/bjd.13845. PMID 25891046. S2CID 22874727.
Wong, G (February 2024). “Options for Multiple Food Allergies — Food Avoidance or Pharmacologic Treatment?”. 《New England Journal of Medicine》 (영어) 390 (10): 946–948. doi:10.1056/NEJMe2400807. ISSN 0028-4793. PMID 38407311. S2CID 267929262.

tga.gov.au

“Australian Public Assessment Report for Omalizumab” (PDF). 《Therapeutic Goods Administration》. April 2021. 2023년 1월 5일에 확인함.
“AusPAR Xolair Omalizumab Novartis Pharmaceuticals Australia Pty Ltd PM-2014-03868-1-5” (PDF). 《Therapeutic Goods Administration》. 2016년 6월 22일. 2023년 1월 5일에 확인함.

worldcat.org

Wong, G (February 2024). “Options for Multiple Food Allergies — Food Avoidance or Pharmacologic Treatment?”. 《New England Journal of Medicine》 (영어) 390 (10): 946–948. doi:10.1056/NEJMe2400807. ISSN 0028-4793. PMID 38407311. S2CID 267929262.